Corindus Vascular Robotics (OTC:CVRS) today touted that its CorPath robotic surgical platform was used in a first-in-human telerobotic intervention study in India.

The Waltham, Mass.-based company touted that the study was the world’s first percutaneous coronary intervention conducted from a remote location outside of a catheterization lab.

In the trial, five patients at India’s Apex Heart Institute underwent an elective PCI procedure from a distance of approximately 20 miles away, Corindus said.

The procedures were performed by Apex Heart Institute chair and chief interventional cardiologist Dr. Tejas Patel from inside the Swaminarayan Akshardham temple in Gandhinagar, while his partner, Dr. Sanjay Shah, attended to the patient in person at the Apex Heart Institute.

“The first in human cases of remote robotic PCI represent a landmark event for interventional medicine. The application of telerobotics in India has the potential to impact a significant number of lives by providing access to care that may not otherwise have been possible. For the first time in cardiology’s history, India will shine for this ground-breaking innovation, and I am honored to be a part of this historic occasion,” Dr. Patel said in a prepared statement.

Corindus said that following the study, it plans to begin commercial product development to allow the CorPath system to be used in remote interventions.

“Cardiovascular disease, including stroke, is the world’s most significant and undertreated clinical problem due to limited access to specialized, timely medical care. As a result of existing barriers to care, including increased global poverty and a declining number of trained specialists, only a fraction of patients worldwide receives life-saving treatment, resulting in substantial death or disability. We anticipate that our technology will revolutionize cardiovascular disease treatment by providing specialized and timely medical care to anyone, anywhere,” prez & CEO Mark Toland said in a press release.

Last month, Corindus saw shares rise over 10% after the robotic surgical platform maker beat loss-per-share expectations on Wall Street with its third quarter earnings.

We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…

The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Qpic.twitter.com/oasI…

Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine#ESMO18pic.twitter.com/41QL…

With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStorypic.twitter.com/Xuoh…

#cardiovascular news CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC - CorFlow Therapeutics AG corflowtherapeutics.… today announced that the company will present fundamental new insights into the coronary microci... ow.ly/OlaG50gAElO